Stryker upgraded by Canaccord Genuity with a new price target

Portage, Michigan, April 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2025 on Thursday, May 1, 2025.  A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's first quarter that ended March 31, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, May 1, 2025, to discuss its first quarter 2025 results.  The webcast can be accessed at Stryker - Events & Presentations.  An archive of the webcast will also be available on the company's website two hours after the

VB Spine is a Strategic Partner to Stryker with Access to Mako Spine and Copilot Marc, John and Anthony Viscogliosi Lead VB Spine as Co-Chief Executive Officers NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Viscogliosi Brothers, LLC, a family-owned investment office specializing in the neuro-musculoskeletal space, today announced the successful completion of its previously announced acquisition of the U.S. spine business from Stryker (NYSE:SYK). The business will operate as a standalone company under the name VB Spine, LLC ("VB Spine"). VB Spine is advancing toward the completion of its acquisition of Stryker's international spine businesses, pending satisfaction of legal and regul

Portage, Michigan, April 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC, as part of the newly formed company VB Spine, LLC. "The sale of our spinal implants business enhances our strategic focus, positioning us to meet evolving customer needs and invest where we see the greatest opportunity for innovation and long-term growth," said Kevin Lobo, Chair and CEO, Stryker. "We remain committed to the spine space through our Interventional Spine, Neurotechnology and Enabling Technologies businesses, as well as our strategic partnership with

Citigroup resumed coverage of Stryker with a rating of Buy and set a new price target of $450.00

Morgan Stanley upgraded Stryker from Equal-Weight to Overweight and set a new price target of $445.00 from $370.00 previously

Wolfe Research initiated coverage of Stryker with a rating of Outperform and set a new price target of $405.00

3 - STRYKER CORP (0000310764) (Issuer)

3 - STRYKER CORP (0000310764) (Issuer)

4 - STRYKER CORP (0000310764) (Issuer)

DEFA14A - STRYKER CORP (0000310764) (Filer)

DEF 14A - STRYKER CORP (0000310764) (Filer)

8-K - STRYKER CORP (0000310764) (Filer)

Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein's decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker's Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025. "I want to thank Glenn for his performance drive, strong business partnership, and excellent leadership of the Finance and IT organizations. Glenn is a growth champion who invested in developing talent, including Preston Wells, who has been promoted to Chief Financial Offi

Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk

Portage, Michigan, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable April 30, 2025 to shareholders of record at the close of business on March 31, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 15

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Reported net sales increased 10.7% to $6.4 billionOrganic net sales increased 10.2%Reported operating income margin of 9.0%Adjusted operating income margin(1) increased 200 bps to 29.2%Reported EPS decreased 52.7% to $1.41Adjusted EPS(1) increased 15.9% to $4.01  Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        10.6        %         (0.5)        %         11.1        %         1.0        %         10.1        

SC 13G/A - STRYKER CORP (0000310764) (Subject)

SC 13G/A - STRYKER CORP (0000310764) (Subject)

SC 13G/A - STRYKER CORP (0000310764) (Subject)